OTC Markets OTCPK - Delayed Quote USD

AstraZeneca PLC (AZNCF)

127.45

-9.45

(-6.90%)

At close: May 12 at 9:30:00 AM EDT

MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD

The approval was based on the propellant clinical development programme outcomes.

Pharmaceutical Technology 26 minutes ago

AZN
London stocks strike month-high after US-China tariff deal

London’s top index finished up by 0.59%, or 50.18 points, to close at 8,604.98.

PA Media: Money 17 hours ago

^FTSE

AZN
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?NYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits Trum

Bloomberg 21 hours ago

AZN

AZNCF
-6.90%

BERZ
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Drugmakers' shares fell globally after President Trump said he would sign an executive order to lower the cost of prescription drugs. Shares of Japan's Daiichi Sankyo, which gets about a third of revenue from the U.S., dropped around 8%. Other Japanese drug stocks also fell.

The Wall Street Journal 22 hours ago

AZN

AZNCF
-6.90%

PFE
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial

The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

Clinical Trials Arena 22 hours ago

AZN
Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices

Pfizer (PFE), AstraZeneca (AZN), Johnson & Johnson (JNJ), and other drug company shares fell in Mond

PREMIUM
MT Newswires 23 hours ago

JNJ

PFE

AZN
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg yesterday

C

TAK

TKPHF
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer. This development coincided with a 5.93% share price increase over the past month. The company's recent announcements, such as the Calquence approval in the EU and positive results from the DESTINY-Breast11 trial, have reinforced its commitment to innovative treatments. While market...

Simply Wall St. 2 days ago

AZN

AZNCF
-6.90%
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 3 days ago

AZN
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.

Zacks 3 days ago

NVO

AZN

JAZZ
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

WILMINGTON, Del., May 09, 2025--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.

Business Wire 3 days ago

AZN

AZNCF
-6.90%
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

Clinical Trials Arena 4 days ago

AZN

4568.T
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal...

Simply Wall St. 5 days ago

AZN

AZNCF
-6.90%
Q1 2025 Arcus Biosciences Inc Earnings Call

Q1 2025 Arcus Biosciences Inc Earnings Call

Thomson Reuters StreetEvents 5 days ago

RCUS

AZN
Expediting parallel drug approval pathways is challenging, but rewarding

A panel at Swiss Biotech Day 2025 discussed three global parallel drug approval pathways.

Pharmaceutical Technology 5 days ago

AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with h

Business Wire 5 days ago

AZN

AZNCF
-6.90%
EC approves AstraZeneca’s Calquence combo to treat MCL

The EC’s decision was supported by outcomes from the ECHO Phase III trial.

Pharmaceutical Technology 6 days ago

AZN
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Tempus AI Inc (TEM) reports a 75.4% revenue increase and a significant $200 million partnership, setting the stage for a promising fiscal year.

GuruFocus.com 6 days ago

TEM

AZN
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.

Fox Business 6 days ago

AZN
AZN or ARGX: Which Is the Better Value Stock Right Now?

AZN vs. ARGX: Which Stock Is the Better Value Option?

Zacks 6 days ago

AZN

Performance Overview

Return	AZNCF	FTSE 100 (^FTSE)
YTD	-2.10%	+5.27%
1-Year	-17.80%	+2.24%
3-Year	+10.93%	+15.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZNCF)

MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD

London stocks strike month-high after US-China tariff deal

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial

Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

Q1 2025 Arcus Biosciences Inc Earnings Call

Expediting parallel drug approval pathways is challenging, but rewarding

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

EC approves AstraZeneca’s Calquence combo to treat MCL

Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing

AZN or ARGX: Which Is the Better Value Stock Right Now?

Performance Overview